Rigenerand, which is working on cGMP gene and cell therapies, developed a 3D bioreactor design for its own use. However, company officials soon began to sell it as a standalone product. The concept is to use it as an accelerator for validating the cell and gene therapy approach, specifically to validate CAR-T products against primary cells or cell lines during research and development.